Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function

Gene Therapy

Volumn 15, Issue 1, 2008, Pages 40-48

  Zhang, H ^a,b   Zhu, S J ^a   Wang, W ^c   Wei, Y J ^a   Hu, S S ^a,b  

^a BEIJING HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CAPILLARY DENSITY; CELL BASED GENE THERAPY; CELL STRUCTURE; CELL TRANSPLANTATION; CHO CELL; CONTROLLED STUDY; CULTURE MEDIUM; DNA MODIFICATION; DRUG RELEASE; EX VIVO GENE TRANSFER; GENE EXPRESSION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HISTOLOGY; HUMORAL IMMUNITY; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MALE; MICROENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANTIBODY FORMATION; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; GENE THERAPY; GENETIC ENGINEERING; IMMUNOHISTOCHEMISTRY; INJECTIONS; MALE; MICROSPHERES; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STAINING AND LABELING; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

CRICETULUS GRISEUS; RATTUS;

EID: 37249094049     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303049     Document Type: Article

References (31)

1. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005; 90: 315-326.
2. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for iscCemic disease: Part II: cell-based therapies. Circulation 2004; 109: 2692-2697.
3. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 2006; 13: 1503-1511.
4. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-2018.
5. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000; 36: 2132-2139.
6. Yau TM, Fung K, Weisel RD, Fujii T, Mickle DA, Li RK. Enhanced myocardial angiogenesis by gene transfer with transplanted cells. Circulation 2001; 104: I218-I222.
7. Penn MS. Cell-based gene therapy for the prevention and treatment of cardiac dysfunction. Nat Clin Pract Cardiovasc Med 2007; 4 (Suppl 1): S83-S88.
8. Zhang H, Fazel S, Tian H, Mickle DA, Weisel RD, Fujii T et al. Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol 2005; 289: H2089-H2096.
9. Chang TM. Semipermeable microcapsules. Science 1964; 146: 524-525.
10. Schneider S, Feilen PJ, Brunnenmeier F, Minnemann T, Zimmermann H, Zimmermann U et al. Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. Diabetes 2005; 54: 687-693.
11. Chen LG, Wang ZR, Wan CM, Xiao J, Guo L, Guo HL et al. Circadian renal rhythms influenced by implanted encapsulated hANP-producing cells in Goldblatt hypertensive rats. Gene Therapy 2004; 11: 1515-1522.
12. Date I, Shingo T, Ohmoto T, Emerich DF. Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells. Exp Neurol 1997; 147: 10-17.
13. Hasse C, Klock G, Schlosser A, Zimmermann U, Rothmund M. Parathyroid allotransplantation without immunosuppression. Lancet 1997; 350 1296-1297.
14. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026.
15. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401: 517-518.
16. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980; 210: 908-910.
17. Chang TM. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 2005; 4: 221-235.
18. Dove A. Cell-based therapies go live. Nat Biotecknol 2002; 20 339-343.
19. Zimmermann H, Zimmermann D, Reuss R, Feilen PJ, Manz B, Katsen A et al. Towards a medically approved technology for alginate-based microcapsules allowing long-term immunoisolated transplantation. J Mater Sci Mater Med 2005; 16: 491-501.
20. Jones KS, Sefton MV, Gorczynski RM. In vivo recognition by the host adaptive immune system of microencapsulated xenogeneic cells. Transplantation 2004; 78: 1454-1462.
21. Yau TM, Li G, Weisel RD, Reheman A, Jia ZQ, Mickle DA et al. Vascular endothelial growth factor transgene expression in cell-transplanted hearts. J Thorac Cardiovasc Surg 2004; 127 1180-1187.
22. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
23. Haque T, Chen H, Ouyang W, Martoni C, Lawuyi B, Urbanska A et al. Investigation of a new microcapsule membrane combining alginate, chitosan, polyethylene glycol and poly-L-lysine for cell transplantation applications. Int J Artif Organs 2005; 28: 631-637.
24. Dusseault J, Tam SK, Ménard M, Polizu S, Jourdan G, Yahia L et al. Evaluation of alginate purification methods: Effect on polyphenol, endotoxin, and protein contamination. J Biomed Mater Res A 2005; 76: 243-251.
25. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-668.
26. Field J, Nikawa J, Broek D, MacDonald B, Rodgers L, Wilson IA et al. Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method. Mol Cell Biol 1988; 8: 2159-2165.
27. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 1996; 98: 1417-1422.
28. Ma X, Vacek I, Sun A. Generation of alginate-poly-l-lysine-alginate (APA) biomicrocapsules: The relationship between the membrane strength and the reaction conditions. Artif Cells Blood Substit Immobil Biotechnol 1994; 22: 43-69.
29. Su W, Zhang H, Jia Z, Zhou C, Wei Y, Hu S. Cartilage-derived stromal cells: Is it a novel cell resource for cell therapy to regenerate infarcted myocardium? Stem Cells 2006; 24: 349-356.
30. Zhang P, Zhang H, Wang H, Wei Y, Hu S. Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif Organs 2006; 30: 86-93.
31. Miyatake T, Sato K, Takigami K, Koyamada N, Hancock WW, Bazin H et al. Complement-fixing elicited antibodies are a major component in the pathogenesis of xenograft rejection. J Immunol 1998; 160 4114-4123.